Unlocking The Role of ECHDC1 in The Citric Acid Cycle (G55862)

Target Name: ECHDC1

NCBI ID: G55862

ECHDC1

Unlocking The Role of ECHDC1 in The Citric Acid Cycle

Enoyl Coenzyme A hydratase domain containing 1 (ECHDC1) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, which is a central metabolic pathway that generates energy in the form of ATP from food molecules.

ECHDC1 is a 21-kDa protein that is composed of 215 amino acid residues. It is located at the end of the alpha-helices of the first transmembrane domain and is responsible for catalyzing the hydration of the TCA cycle's last step, the citric acid cycle intermediates.

The citric acid cycle is a crucial metabolic pathway that is involved in the production of energy in the form of ATP from food molecules. It is a complex process that involves the breakdown of food molecules into smaller intermediates, followed by the production of ATP and the production of carbon dioxide as a byproduct.

ECHDC1 is a key enzyme in this cycle, as it catalyzes the hydration of the TCA cycle's last step. This step involves the production of the citric acid cycle intermediates, including the 2-carboxylic acid (2-CA) and the 3-carboxylic acid (3-CA) intermediates.

The production of ATP from the citric acid cycle is critical for the survival of all living organisms. It is the primary source of energy for the cell and is used to maintain the integrity of the cell membrane, synthesize new DNA and RNA, and support various cellular processes.

ECHDC1 is a potential drug target or biomarker because of its role in the production of ATP from the citric acid cycle. By inhibiting the activity of ECDC1, researchers may be able to reduce the production of ATP and disrupt the normal function of the citric acid cycle . This could have therapeutic implications for a variety of diseases, including cancer, cardiovascular disease, and neurological disorders.

In addition to its role in the production of ATP, ECDC1 is also involved in the regulation of cellular processes. It has been shown to be involved in the production of various signaling molecules, including insulin and erythropoietin.

ECHDC1 is also a good candidate as a biomarker for certain diseases. For example, it has been shown to be downregulated in various diseases, including cancer, cardiovascular disease, and neurological disorders. This suggests that its levels may be useful as a diagnostic or therapeutic target.

In conclusion, ECDC1 is a protein that is involved in the production of ATP from the citric acid cycle and is also involved in the regulation of cellular processes. It is a potential drug target or biomarker and may be useful for the treatment of various diseases. Further research is needed to fully understand its role in these processes and to develop effective therapies.

Protein Name: Ethylmalonyl-CoA Decarboxylase 1

Functions: Decarboxylates ethylmalonyl-CoA, a potentially toxic metabolite, to form butyryl-CoA, suggesting it might be involved in metabolite proofreading (PubMed:22016388). Also has methylmalonyl-CoA decarboxylase activity at lower level (By similarity)

The "ECHDC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ECHDC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets